Skip to main content
Explore URMC

Richard Dunne, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-8762

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



When a patient is diagnosed with cancer, he or she is faced with a lot of questions and uncertainty of what the future holds. My philosophy is to provide as much information as possible so that patients can make the best decisions for themselves and their families and so that together we can face any fears or worries head on.

I chose this field because my hope is to make the lives of cancer patients better – whether it is through direct patient care or my research, which focuses on pancreatobiliary cancers, as well as weight loss and muscle wasting related to cancer.

In addition to being passionate about cancer care, I have many interests outside of work that I enjoy sharing with my patients such as sports, travel and music.

Conditions I Treat

- Esophageal cancer
- Gastric cancer
- Liver cancer
- Pancreatic cancer
- Colorectal cancer
- Anal cancer



  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine


MD | SUNY Downstate College of Medicine

Post-doctoral Training & Residency

07/01/2016 - 6/30/2019
Research in Research at University of Rochester Medical Center

07/01/2013 - 06/30/2015
Fellowship in Hematology/Oncology at University of Rochester Medical Center

06/25/2010 - 06/24/2012
Residency in Internal Medicine at University of Rochester Medical Center

06/25/2009 - 06/24/2010
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL expand_more


2019 - 2021
CTSI KL2 Career Development Award
Location: University of Rochester Medical Center

2017 - 2018
Department of Medicine Research Pilot Grant Award

2016 - 2019
NIH R25 Fellowship Training Program in Cancer Control
Location: University of Rochester Medical Center

2015 - 2018
Wilmot Foundation for Cancer Research Fellowship Award

VIEW ALL expand_more

Clinical Trials

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Lead Researcher: Richard F Dunne

The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

View Study Details

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Lead Researcher: Richard F Dunne

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

View Study Details

Evaluating the Effects of Dietary Supplementation With Remune on Cancer Associated Weight and Muscle Loss With and Without Exercise: A Randomized Pilot Feasibility Study.

Lead Researcher: Richard F Dunne

The main purpose of this research study is to determine if the use of a nutritional supplement and exercise improve or worsen cachexia.

View Study Details

Neoadjuvant FOLFOX therapy with Short Course Radiation and active surveillance in locally advanced Rectal Cancer

Lead Researcher: Richard F Dunne

The purpose of this study is to evaluate the treatment of patients with locally advanced rectal cancer for complete response to neoadjuvant chemotherapy without the use of radiation and surgery.

View Study Details

Double-Blinded, Placebo-Controlled Trial to Explore the Anti-Androgen, Ketoconazole, for Treating Patients With an Ongoing Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash

Lead Researcher: Richard F Dunne

This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.

View Study Details

Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study

Lead Researcher: Richard F Dunne

Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer.

View Study Details

UGIM-16011: Evaluating the Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in patients with Cancer of the Upper Gastrointestinal Tract with Pre-cachexia or Cachexia: A Pilot Study

Lead Researcher: Richard F Dunne

We would also like to find out if this exercise intervention improves physical performance, day-to-day function, quality of life, and how the exercise may affect markers of inflammation in the blood over time. Cancer cachexia is a complex condition that can result in weight loss, muscle weakness, and/or tiredness, and may affect your normal daily activities and quality of life. Cachexia is common in patients with upper gastrointestinal tract cancers (esophageal, stomach, bile duct or liver cancer, and pancreatic cancer). There is little information on how these symptoms may develop or change as cachexia progresses, or how exercise may help improve these symptoms. Currently more information is needed on how physical performance and quality of life is affected by cachexia. There are no drugs approved for cachexia so understanding cachexia and its effect on the body may guide the development of interventions to help other patients with cancer cachexia.

View Study Details


Journal Articles

Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, Flannery MA, Obrecht S, Gilmore N, Ramsdale E, Dunne RF, Wildes T, Plumb S, Patil A, Wells M, Lowenstein L, Janelsins M, Mustian K, Hopkins JO, Berenberg J, Anthony N, Dale W. "Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study." Lancet.. 2021 Nov 3; Epub 2021 Nov 03.

Mohamed MR, Kyi K, Mohile SG, Xu H, Culakova E, Loh KP, Flannery M, Obrecht S, Ramsdale E, Patil A, Dunne RF, DiGiovanni G, Hezel A, Burnette B, Desai N, Giguere J, Magnuson A. "Prevalence of and factors associated with treatment modification at first cycle in older adults with advanced cancer receiving palliative treatment." Journal of geriatric oncology.. 2021 Jul 13; Epub 2021 Jul 13.

Kleckner AS, Wells M, Kehoe LA, Gilmore NJ, Xu H, Magnuson A, Dunne RF, Jensen-Battaglia M, Mohamed MR, O'Rourke MA, Vogelzang NJ, Dib EG, Peppone LJ, Mohile SG. "Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer." . 2021 Jul 6; :OP2100196. Epub 2021 Jul 06.